These findings reinforce the concept that modulation of IL-1 is a viable target for interventions aimed at preventing heart failure after AMI, and, within the challenges and limitations of preclinical and translational studies [15], they provide the frame to interpret studies using pharmacologic IL-1 blockers in patients with AMI [16]. The gene discussed is IL1A; the disease is heart failure.